BioSpace News Archive

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will release its second quarter 2019 earnings results on Tuesday, July 30, 2019 after the close of the market.

Combination of Technology and Intelligence Will Help Enhance Safety, Control and Efficiency

On July 15th, Krishnan Suthanthiran, President & Founder of TeamBest Companies and Best Cure Foundation, presented the AAPM Best Award to the 2019 recipients at the Annual Meeting of the American Association of Physicists in Medicine taking place in San Antonio, Texas, USA July 14–17, 2019.

Servier and BioCurate will collaborate under the terms of a memorandum of understanding (MOU), whereby they will work together, both directly and via participation in BioCurate’s Industry and Scientific Advisory Committee, in providing advice and assessing new therapeutic candidates arising from BioCurate’s academic partners.

Altaire Pharmaceuticals, Inc., announces that it is correcting its July 3, 2019 Announcement of a Voluntary Recall for Over-the-Counter drug products and lots, within expiry, sold at Wal-Mart during the time period as indicated in the tables below.

The security of AEL’s systems was not affected by this incident.

If you purchased or otherwise acquired OMCL securities on or before July 10, 2019 and suffered losses or have information that may assist the firm’s investigation contact Hagens Berma

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced that on Sunday, its co-founder, Lars Lannfelt, professor in geriatrics at Uppsala University and researcher, received one of the world’s most prestigious awards in Alzheimer’s disease research.

New Hope Fertility Center, through our technology and innovation, has protected all of our patients’ specimens throughout the terrible hours of the NYC blackout.

Filterlex Medical is a medical device start-up company, developing an innovative embolic protection device (CAPTIS) for reducing the risk of stroke and other complications during catheter-based structural heart procedures.